Cordis Counters TAXUS IV With “New SIRIUS,” Critiques Angiographic Data

The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis